Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
7,582
datasets available to search
ShareScore release 0.9.0
Dataset results
7,582 results for “clinical study”
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adu
ClinicalTrials.gov study NCT05415722. IPD Sharing: NO. Countries: 1. Publications: 1.
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATIT
ClinicalTrials.gov study NCT02145468. IPD Sharing: YES. Countries: 34. Publications: 3.
Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD
ClinicalTrials.gov study NCT04052698. IPD Sharing: UNDECIDED. Countries: 8. Publications: 14.
A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
ClinicalTrials.gov study NCT00675987. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice
ClinicalTrials.gov study NCT01474291. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study
ClinicalTrials.gov study NCT02489773. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
ClinicalTrials.gov study NCT03162783. IPD Sharing: NO. Countries: 1. Publications: 1.
Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients
ClinicalTrials.gov study NCT05502081. IPD Sharing: YES. Countries: 1. Publications: 10.
Data from: Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson’s disease: A retrospective study
Open the record for dataset details and reuse information.
Data from: Low levels of hypertension screening in HIV care clinics in rural Uganda: a mixed methods study
Open the record for dataset details and reuse information.
Data from: Implementation of a pediatric telemedicine and medication delivery service in a resource-limited setting: A pilot study for clinical safety and feasibility
Open the record for dataset details and reuse information.
Data from: Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: A multicentre clinical study of two end-to-end commercial workflows
Open the record for dataset details and reuse information.
Data from: Effect of mitochondrial oxidative stress on regulatory T cell manufacturing for clinical application in transplantation: Results from a pilot study
Open the record for dataset details and reuse information.
Data from: Clinical management and mortality among COVID-19 cases in sub-Saharan Africa: a retrospective study from Burkina Faso and simulated case analysis.
<p>Absolute numbers of COVID-19 cases and deaths reported to date in the sub-Saharan Africa (SSA) region have been relatively low. As a result, there has been limited investigation into deceased cases in the region, as well as the impacts of different case management strategies. We detail demographic, epidemiological, and clinical information derived from publicly available information on deceased cases in SSA and, for cases in Burkina Faso, from aggregate records at the Center Hospitalier Universitaire de Tengandogo. Logistic regression was conducted on a synthetic case population to evaluate the adjusted odds of survival for patients receiving oxygen therapy or convalescent plasma, based on therapeutic effectiveness observed for other respiratory illnesses. Across SSA, deceased cases have been predominantly male and over 50 years of age. After adjustment for sex, age, and underlying conditions, the odds of mortality among cases in the synthetic population not receiving oxygen therapy was significantly higher than those receiving oxygen (OR: 2.07; 95%CI: 1.56-2.75). Cases receiving convalescent plasma had 50% reduced odds of mortality (95%CI: 0.24-0.93).<b> </b>Investment in sustainable oxygen therapy could reduce COVID-19 deaths in SSA. Ongoing investigation into convalescent plasma is warranted, as data on its effectiveness specifically in treating COVID-19 becomes available.</p>
Dataset of Correlation of clinical decision-making with probability of disease: A web-based study among general practitioners
<p>In databases we find the following information:</p> <p>- the true probability of the disease in the clinical vignette<br> - the probability of the disease estimated by the general practitioner (GP) in the clinical vignette<br> - the clinical decision of the general practitioner<br> - the baseline characteristics of the participants</p>
A novel clinical model for predicting malignancy of solitary pulmonary nodules: A multicenter study in Chinese population
<p><strong>Supplementary Data</strong></p> <p> </p> <p>Supplement Figure 1: The calibration curves for the novel model in training cohort (A), internal validation cohort (B) and external validation cohort (C), respectively.</p> <p> </p> <p>Supplement Table 1. Demographics and clinical characteristics of patients from Sun Yat-sen University Cancer Center.</p> <p> </p> <p>Supplement Table 2. Demographics and clinical characteristics of patients from Henan Tumor Hospital.</p> <p> </p> <p>Supplement Table 3. Comparison of the sensitivity, specificity, positive likelihood ratio, negative likelihood ratio of the three models analyzed in this study</p> <p> </p> <p>Supplement Table 4. The correlation between our model, PKUPH model and Mayo model</p>
Data from: Quantifying patient preferences for symptomatic breast clinic referral: a decision analysis study
Objectives: Decision analysis study that incorporates patient preferences and probability estimates to investigate the impact of women's preferences for referral or an alternative strategy of watchful waiting if faced with symptoms that could be due to breast cancer. Setting: Community-based study. Participants: Asymptomatic women aged 30-60 years. Interventions: Participants were presented with 11 health scenarios that represent the possible consequences of symptomatic breast problems. Participants were asked the risk of death that they were willing to take in order to avoid the health scenario using the standard gamble (SG) utility method. This process was repeated for all 11 health scenarios. Formal decision analysis for the preferred individual decision was then estimated for each participant. Primary outcome measure: The preferred diagnostic strategy, either watchful waiting or referral to a breast clinic. Sensitivity analysis was used to examine how each varied according to changes in the probabilities of the health scenarios. Results: A total of 35 participants completed the interviews, with median age 41 years (Interquartile range 35 to 47 years). The majority of the study sample were employed (n=32, 91.4%), with a third-level (university) education (n=32, 91.4%) and with knowledge of someone with breast cancer (n=30, 85.7%). When individual preferences were accounted for, 25 (71.4%) patients preferred watchful waiting to referral for triple assessment as their preferred initial diagnostic strategy. Sensitivity analysis shows that referral for triple assessment becomes the dominant strategy at the upper probability estimate (18%) of breast cancer in the community. Conclusions: Watchful waiting is an acceptable strategy for most women who present to their GP with breast symptoms. These findings suggest that current referral guidelines should take more explicit account of women's preferences in relation in terms of the initial diagnostic strategy for symptomatic breast problems.
Data from: Outcome of breast cancer in Moroccan young women correlated to clinic-pathological features, risk factors and treatment: a comparative study of 716 cases in a single institution
Background: Breast cancer in young women is quite uncommon and shows more aggressive characteristics with major disparities between worldwide populations. Prognosis and outcome of breast cancer in young patients are widely studied, but still no consensus is available. Methods: We retrospectively included 716 cases of breast cancer women diagnosed in 2009 at the National Institute of Oncology of Rabat. Patients were divided into two groups according to their age: women aged ≤40 years (Group 1) and women aged >40 years (Group 2). Data were recorded from patients' medical files and analyzed using SPSS 13.0 software (IBM). Results: Young patients represent 24.9% of all patients with breast cancer. The comparison between the two groups displayed significant differences regarding nulliparity (p = 0.001) and progesterone receptor negativity (p = 0.01). Moreover, more progression (Metastases/Relapse) was registered in young women as compared to older women with breast cancer (p = 0.03). The estimated median follow-up period was 31 months. The 5-years Event-Free Survival (EFS) of patients with local disease was 64.6% in young women and 71.5% in older women with breast cancer (p = 0.04). Multivariate analysis in young women showed that nulliparity (HR: 7.2; 95%CI: 1.16–44.54; p = 0.03), T3 tumors (HR: 17.39; 95%CI: 1.74–173.34; p = 0.01) and negative PgR status (HR: 19.85; 95%CI: 1.07–366.54; p = 0.04) can be considered as risk factors for poorer event free survival while hormone therapy was associated with better EFS (HR: 0.11; 95%CI: 0.00–0.75; p = 0.03). In Group 2, multivariate analysis showed that patients with inflammatory breast cancer, N+ status, absence of radiotherapy, absence of chemotherapy, and absence of hormone therapy are at increased risk of recurrence. Conclusions: In Morocco, breast cancer is more frequent in young women as compared to western countries. Breast cancer in young women is more aggressive and is diagnosed late, leading to an intensive treatment. Moreover, the main factors associated with breast cancer development in young women would be hormonal and reproductive status. Analysis of other genetic biomarkers is needed to explain the high prevalence of breast cancer in young women to improve breast cancer management in Morocco
Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of hepatitis E genotype 3: a prospective study
<p class="CxSpFirst">High hepatitis E (HEV) seroprevalence has been reported in the general population and in post-liver transplant (LT) cases in several regions, including Thailand, with genotype 3 being a predominant genotype. We hypothesized that HEV might persist at a subclinical level and might pose clinical risks in the post-LT period. We performed a cross-sectional study with 108 post-LT patients and found an IgG seroprevalence of 55.6%. Subsequently, 91 cases without clinical evidence of HEV-related hepatitis were enrolled in 1 year of prospective follow-up to determine clinical status, serologies and serum/feces HEV RNA every 4 months. HEV RNA was detected, indicating subclinical infections in patients with or without seropositivity, with an annual incidence of 7.7%. Our results suggest that subclinical HEV infection exists among LT patients in this high-prevalence area. Thus, clinicians should be aware of the possibility of disease reemergence and HEV viral transmission in LT patients.</p>
Data from: Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices
Objectives: To develop and pilot a tool to measure and improve pharmaceutical companies' clinical trial data sharing policies and practices. Design: Cross sectional descriptive analysis. Setting: Large pharmaceutical companies with novel drugs approved by the US Food and Drug Administration in 2015. Data sources: Data sharing measures were adapted from 10 prominent data sharing guidelines from expert bodies and refined through a multi-stakeholder deliberative process engaging patients, industry, academics, regulators, and others. Data sharing practices and policies were assessed using data from ClinicalTrials.gov, Drugs@FDA, corporate websites, data sharing platforms and registries (eg, the Yale Open Data Access (YODA) Project and Clinical Study Data Request (CSDR)), and personal communication with drug companies. Main outcome measures: Company level, multicomponent measure of accessibility of participant level clinical trial data (eg, analysis ready dataset and metadata); drug and trial level measures of registration, results reporting, and publication; company level overall transparency rankings; and feasibility of the measures and ranking tool to improve company data sharing policies and practices. Results: Only 25% of large pharmaceutical companies fully met the data sharing measure. The median company data sharing score was 63% (interquartile range 58-85%). Given feedback and a chance to improve their policies to meet this measure, three companies made amendments, raising the percentage of companies in full compliance to 33% and the median company data sharing score to 80% (73-100%). The most common reasons companies did not initially satisfy the data sharing measure were failure to share data by the specified deadline (75%) and failure to report the number and outcome of their data requests. Across new drug applications, a median of 100% (interquartile range 91-100%) of trials in patients were registered, 65% (36-96%) reported results, 45% (30-84%) were published, and 95% (69-100%) were publicly available in some form by six months after FDA drug approval. When examining results on the drug level, less than half (42%) of reviewed drugs had results for all their new drug applications trials in patients publicly available in some form by six months after FDA approval. Conclusions: It was feasible to develop a tool to measure data sharing policies and practices among large companies and have an impact in improving company practices. Among large companies, 25% made participant level trial data accessible to external investigators for new drug approvals in accordance with the current study's measures; this proportion improved to 33% after applying the ranking tool. Other measures of trial transparency were higher. Some companies, however, have substantial room for improvement on transparency and data sharing of clinical trials.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.